BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 13, 2017--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the Leerink Partners 6th Annual Global Healthcare
Conference on Wednesday, February 15 at 2:30pm Eastern Time. The
presentation will be webcast live and available for replay from Seattle
Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company that develops
and commercializes novel antibody-based therapies for the treatment of
cancer. The company’s industry-leading antibody-drug conjugate (ADC)
technology harnesses the targeting ability of antibodies to deliver
cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab
vedotin), the company’s lead product, in collaboration with Takeda
Pharmaceutical Company Limited, is the first in a new class of ADCs
commercially available globally in 66 countries for relapsed classical
Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell
lymphoma (sALCL). Seattle Genetics is also advancing vadastuximab
talirine (SGN-CD33A; 33A), an ADC in a phase 3 trial for acute myeloid
leukemia. Headquartered in Bothell, Washington, Seattle Genetics has a
robust pipeline of innovative therapies for blood-related cancers and
solid tumors designed to address significant unmet medical needs and
improve treatment outcomes for patients. The company has collaborations
for its proprietary ADC technology with a number of companies including
AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer.
More information can be found at www.seattlegenetics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170213005145/en/
Source: Seattle Genetics, Inc.
Seattle Genetics, Inc.